Squamous cell carcinoma of the cervix – Diagnostics – Overview of Information and Clinical Research

Diagnosing squamous cell carcinoma of the cervix is a multi-step process that combines screening tests, physical examinations, and tissue analysis to identify abnormal cells before they become invasive cancer or to confirm the presence of disease.

Introduction: Who Should Undergo Diagnostics and When

Squamous cell carcinoma of the cervix is the most common type of cervical cancer, accounting for between 80 and 90 percent of all cervical cancer cases. This cancer develops in the flat, skin-like cells that cover the outer surface of the cervix, particularly in an area called the transformation zone or squamocolumnar junction, where two different types of cervical cells meet.^[1]^[3]

Regular diagnostic screening is recommended for all women who have a cervix, typically beginning around age 21 or 25, depending on local guidelines. The importance of screening cannot be overstated, as cervical cancer often develops slowly over many years, giving healthcare providers multiple opportunities to detect and treat precancerous changes before they become invasive cancer. Women who have not had regular screening tests are at higher risk of developing cervical cancer because these tests can identify abnormal cells that may later turn into cancer.^[3]^[10]

You should seek diagnostic testing if you experience any warning signs of cervical cancer. In the early stages, cervical cancer often causes no symptoms, which is why screening is so important. However, if the disease progresses, you might notice watery or bloody vaginal discharge that may be heavy and have a foul odor, bleeding after sexual intercourse, bleeding between menstrual periods or after menopause, or pain during sex. If cancer has spread to nearby tissues, you may experience difficult or painful urination, sometimes with blood in your urine, diarrhea or bleeding from the rectum, ongoing fatigue and weight loss, a general feeling of illness, or dull backache and swelling in the legs.^[3]^[10]

Even without symptoms, certain factors increase your need for regular screening. These include infection with high-risk types of Human Papillomavirus (HPV), which causes almost all cervical cancers, having multiple sexual partners, smoking cigarettes, long-term use of birth control pills, a weakened immune system from HIV or medications, or having had three or more full-term pregnancies. Women whose mothers took the medication DES during pregnancy also face higher risk.^[3]^[13]

⚠️ Important

Early stages of cervical cancer are often hard to detect because they don’t usually involve symptoms. This is why regular screening tests like Pap tests are crucial even when you feel perfectly healthy. Most cervical cancers can be prevented if precancerous changes are detected and treated before they progress to invasive disease.

Diagnostic Methods for Identifying the Disease

The diagnosis of squamous cell carcinoma of the cervix begins with screening tests that can detect changes in cervical cells long before cancer develops. The primary screening tool is the Papanicolaou smear, commonly known as the Pap test. This simple procedure involves collecting cells from the surface of the cervix during a pelvic examination. The cells are then examined under a microscope to look for abnormalities. The universal application of Pap smear screening has resulted in early detection of precancerous lesions, which can be removed before they progress to invasive cancer.^[1]^[11]

Another important screening test is HPV testing, which looks for the presence of high-risk types of the human papillomavirus in cervical cells. HPV infections cause most cervical cancers, particularly infections with serotypes 16 and 18. HPV testing can be done at the same time as a Pap test using the same cell sample, or it may be used on its own as a primary screening method. The combination of Pap and HPV testing provides more comprehensive information about your cervical health.^[1]^[4]

If screening tests reveal abnormal results, your healthcare provider will recommend further diagnostic procedures. A colposcopy is often the next step. During this examination, your doctor uses a special magnifying instrument called a colposcope to closely examine your cervix, vagina, and vulva. The colposcope does not enter your body but allows the doctor to see your cervical tissue in much greater detail than during a regular pelvic exam. If abnormal areas are identified during colposcopy, your doctor will likely take a small tissue sample for further testing.

A cervical biopsy involves removing a small piece of cervical tissue for examination under a microscope. This is the definitive way to determine whether abnormal cells are precancerous or cancerous. There are several types of cervical biopsies. A simple biopsy removes a small piece of visible abnormal tissue. An endocervical curettage uses a narrow instrument to scrape cells from the inside of the cervical canal, an area that cannot be seen during colposcopy. A cone biopsy or conization removes a larger, cone-shaped piece of tissue from the cervix and can be both diagnostic and therapeutic, as it may remove all of the abnormal tissue.

Once a diagnosis of invasive cervical cancer is confirmed, additional tests help determine the extent or stage of the disease. Staging is crucial because it guides treatment decisions. Imaging tests play an important role in staging. A computed tomography (CT) scan uses X-rays to create detailed cross-sectional images of your body, helping doctors see if cancer has spread to lymph nodes or other organs. Magnetic resonance imaging (MRI) uses magnets and radio waves to produce detailed images of soft tissues, providing excellent visualization of the cervix, uterus, and surrounding structures. Positron emission tomography (PET) scans may be used to detect cancer that has spread to distant parts of the body.^[4]

Your doctor may also recommend a cystoscopy, where a thin tube with a camera is inserted through your urethra to examine your bladder, or a proctoscopy, which examines your rectum. These procedures help determine if cancer has spread to nearby organs. Blood tests assess your overall health and organ function, which is important when planning treatment.

Understanding the type of cervical cancer is essential because different types may behave differently. The diagnosis will specify whether you have squamous cell carcinoma or another type. Squamous cell carcinomas can be further classified as keratinizing, meaning they contain a tough protein called keratin, or non-keratinizing, meaning they don’t. Rare types of squamous cell carcinoma include verrucous carcinoma, papillary squamous cell carcinoma, warty carcinoma, and basaloid squamous cell carcinoma.^[5]^[6]

The grade of the cancer cells is another important diagnostic detail. Grading describes how much the cancer cells look like normal cells when examined under a microscope. Grade 1 (low grade) cells look most like normal cells, grade 2 cells look somewhat abnormal, and grade 3 (high grade) cells look very abnormal and quite different from normal cells. Higher grade cancers tend to grow and spread more quickly.^[5]

Diagnostics for Clinical Trial Qualification

When patients are being considered for participation in clinical trials testing new treatments for squamous cell carcinoma of the cervix, they must undergo specific diagnostic tests to determine if they meet the study’s enrollment criteria. These qualification tests ensure that participants have the right stage and type of disease to benefit from the experimental treatment being studied.

Standard diagnostic procedures form the foundation of clinical trial screening. Patients must have a confirmed diagnosis of cervical cancer through a biopsy that has been examined by a pathologist. The pathology report must clearly identify the cancer as squamous cell carcinoma or specify if it is mixed with other cell types. This tissue diagnosis is mandatory because clinical trials often target specific cancer types, and squamous cell carcinomas may respond differently to treatments than adenocarcinomas or other cervical cancer types.^[13]

Imaging studies are crucial for determining if a patient meets the stage requirements for a clinical trial. Most trials specify which stages of disease they are studying, whether early-stage localized cancer or advanced metastatic disease. Patients undergo CT scans, MRI scans, or PET scans to precisely measure tumor size and identify any spread to lymph nodes or distant organs. These baseline imaging studies also provide comparison points to measure how well the experimental treatment works during the trial.

Blood tests are routinely required to assess whether patients are healthy enough to tolerate the experimental treatments. These include complete blood counts to check levels of red blood cells, white blood cells, and platelets; liver function tests to ensure the liver can process medications; kidney function tests to confirm the kidneys can eliminate drugs from the body; and other chemistry panels to evaluate overall health status. Some trials may require specific blood tests, such as tumor markers or genetic tests looking for particular molecular features of the cancer.

Many modern clinical trials for cervical cancer require HPV testing to determine which type of HPV caused the cancer. Certain trials may specifically target cancers caused by HPV-16 or HPV-18, or they may require confirmation that the cancer is HPV-positive before enrollment. This information helps researchers understand which patients are most likely to respond to treatments that target HPV-related mechanisms.

Performance status assessments evaluate how well patients can carry out daily activities. Clinical trials use standardized scales to rate whether patients are fully active, have some limitations, or are unable to work. Only patients meeting specific performance criteria can enroll, as the experimental treatments may be too demanding for those who are very ill or frail.

Some clinical trials investigating targeted therapies or immunotherapies require specialized molecular testing of the tumor tissue. These tests look for specific genetic mutations, protein expressions, or other biomarkers that predict whether the experimental treatment will work. For example, trials of immunotherapy drugs may test for PD-L1 expression, a protein that affects how the immune system interacts with cancer cells. Tissue samples from the original biopsy or a new biopsy may be sent to specialized laboratories for these sophisticated analyses.

⚠️ Important

Participating in a clinical trial requires meeting specific medical criteria documented through diagnostic tests. While this may seem like a lot of testing, these requirements protect patient safety and ensure the research produces meaningful results. If you’re interested in clinical trials, discuss with your healthcare provider whether your diagnostic results suggest you might be eligible for any studies.

Documentation of previous treatments is another diagnostic requirement for many clinical trials. Patients may need to have failed certain standard treatments or be newly diagnosed without prior therapy, depending on what the trial is studying. Medical records showing dates and types of previous treatments, along with scans demonstrating how the cancer responded, become part of the diagnostic package for trial enrollment.

Finally, some trials require repeat biopsies during the study to analyze how the tumor is responding to treatment at a cellular level. These research biopsies help scientists understand the biological mechanisms of the experimental therapy but are not part of routine clinical care. Patients considering trials should understand whether additional biopsies will be required and factor this into their decision-making.

Prognosis and Survival Rate

Prognosis

The prognosis for squamous cell carcinoma of the cervix depends heavily on the stage at which the cancer is detected. Women diagnosed with early-stage cervical cancer generally have excellent outcomes, while those with advanced disease face more challenging circumstances. The stage of cancer, which describes how large the tumor is and whether it has spread beyond the cervix, is the most important factor affecting prognosis. Other factors that influence outcomes include the grade of the cancer cells, with higher-grade tumors tending to grow and spread more quickly, and the overall health and age of the patient.^[13]

Most women with cervical cancer are diagnosed at an early stage and can be cured, though they might experience side effects from treatment, such as infertility. The average age of diagnosis is around 49 years, affecting women most commonly between ages 35 and 44. When cervical cancer is found early through regular screening, precancerous changes can often be treated before they become invasive, essentially preventing cancer from developing at all.^[7]^[10]

Women diagnosed with advanced cancer or recurrent cervical cancer typically face a more serious prognosis. Advanced cervical cancer refers to disease that has spread beyond the cervix to nearby tissues or distant organs. When cancer returns after initial treatment, it is called recurrent disease. In these situations, treatment aims to control the cancer, manage symptoms, and extend life, though a cure may not be possible. Women with advanced or recurrent cervical cancer typically have a life expectancy of fewer than two years, though individual outcomes vary considerably based on many factors including the specific characteristics of the cancer and how it responds to treatment.^[7]

Survival Rate

Long-term survival data for squamous cell carcinoma of the cervix treated with radiation therapy shows encouraging results for many patients. In one large study of patients treated with radiation therapy alone between 1971 and 1995, the five-year survival rates varied significantly by stage. For stage Ib disease, where cancer is confined to the cervix but visible, the five-year survival rate was 93.5 percent, and the ten-year survival rate was 90.9 percent. For stage II disease, where cancer has spread beyond the cervix but not to the pelvic wall or lower third of the vagina, the five-year survival rate was 77.0 percent and the ten-year survival rate was 74.5 percent. For stages III and IVa, representing more advanced local disease, the five-year survival rate was 60.3 percent and the ten-year survival rate was 56.1 percent.^[14]

These survival statistics represent older treatment methods and may not reflect current outcomes with modern therapies. Today’s treatments often combine surgery, radiation, chemotherapy, and newer targeted therapies or immunotherapy drugs, potentially leading to improved survival rates compared to historical data. However, these numbers help illustrate that early detection through screening significantly improves the chances of long-term survival.

It’s important to understand that survival statistics are based on large groups of patients and cannot predict exactly what will happen to any individual person. Your own prognosis depends on many unique factors including the specific characteristics of your cancer, your overall health, how well your cancer responds to treatment, and advances in medical care that occur over time. Your healthcare team can provide more personalized information based on your specific situation.

#1 Clinical Trials Search in Europe